Chapter 6

Psychocardiology: The Effects of Stress, Depression, and Anxiety on the Cardiovascular System

Mehmet Semih Belpınar[1]

Abstract

Psychocardiology is an emerging interdisciplinary field that explores the intricate interactions between psychological states and cardiovascular health. Growing evidence suggests that stress, depression, and anxiety significantly influence the onset, progression, and prognosis of cardiovascular diseases (CVDs). Chronic psychological stress activates the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system, leading to sustained elevations in cortisol and catecholamines, which contribute to endothelial dysfunction, hypertension, and arrhythmias. Depression has been associated with increased platelet reactivity, systemic inflammation, and poor adherence to medical therapies, all of which exacerbate cardiovascular risk. Similarly, anxiety disorders are linked to autonomic imbalance and exaggerated cardiovascular responses, increasing susceptibility to myocardial ischemia and sudden cardiac death. Importantly, these psychological conditions not only contribute to the pathophysiology of CVDs but also worsen outcomes in patients with established cardiac conditions. Psychocardiology aims to integrate mental health assessment and interventions into cardiovascular care, emphasizing the importance of a holistic, biopsychosocial approach. Early identification and management of psychological risk factors are crucial for preventing cardiovascular morbidity and improving long-term prognosis. This chapter reviews the biological mechanisms, clinical evidence, and therapeutic implications of stress, depression, and anxiety in the context of cardiovascular disease.

1 Sivas Numune Hastanesi, mehmetsemihbelpinar@gmail.com, https://orcid.org/0000-0002-6768-3710

https://doi.org/10.58830/ozgur.pub779.c3251

Introduction

Psychocardiology, an emerging interdisciplinary field, focuses on the interplay between psychological factors—particularly stress, depression, and anxiety—and cardiovascular health.[1] Mental health and cardiology have long been viewed as separate disciplines. However, mounting evidence reveals that psychosocial stressors significantly affect cardiovascular morbidity and mortality.[2] With cardiovascular diseases (CVDs) remaining a leading cause of mortality worldwide, understanding the influence of psychological factors is critical in designing comprehensive prevention and treatment strategies.[3]

Despite considerable advances in pharmacotherapy, surgical interventions, and preventive cardiology, the persistent burden of CVD suggests that there are underlying contributors beyond the traditional risk factors—hypertension, dyslipidemia, diabetes, and smoking.[4] Stress, depression, and anxiety can act as both independent and synergistic predictors of poor cardiovascular outcomes, including hypertension, atherosclerosis, arrhythmias, and myocardial infarction.[5] Moreover, these psychological factors may impede adherence to recommended medical therapies and lifestyle changes, further exacerbating cardiovascular risk.[6]

This chapter aims to provide an overview of the pathophysiological mechanisms through which stress, depression, and anxiety influence cardiovascular health and disease. Emphasis will be placed on the physiological pathways, epidemiological evidence, and clinical implications for assessment, prevention, and treatment within a psychocardiology framework.

1. Conceptual Foundations of Psychocardiology

1.1 Historical Context

The relationship between psychological factors and cardiac function has intrigued researchers for decades. Early works in psychosomatic medicine proposed that emotional states could precipitate myocardial infarction and exacerbate angina symptoms.[7] Over time, systematic research has elucidated specific mechanisms and pathways that bridge mind and heart. The American Heart Association and other professional bodies now recognize stress, depression, and anxiety as important risk modifiers for cardiovascular disease.[8]

1.2 Definition of Psychocardiology

Psychocardiology is best described as an integrative approach that combines cardiology, psychology, psychiatry, and behavioral medicine to

address the psychological variables that contribute to the development, progression, and management of cardiovascular diseases.[9] This field underscores the bidirectional interplay wherein cardiac conditions can induce psychological distress (e.g., post-myocardial infarction depression), while psychological distress can precipitate or worsen cardiac conditions.[10]

1.3 Scope and Importance

In the last two decades, robust data have shown that psychological factors not only elevate the risk of incident CVD but also worsen outcomes in patients with established heart disease.[11,12] Patients with depression or anxiety have higher rates of hospital readmission, reduced quality of life, and increased mortality after acute coronary syndromes.[13] Consequently, psychocardiology provides a critical framework for prevention, risk stratification, and holistic patient care.

2. Stress and Cardiovascular Health

2.1 Defining Stress and Its Subtypes

Stress refers to a state of threatened homeostasis, which initiates a cascade of physiological and behavioral responses to re-establish equilibrium.[14] Stress may be acute (short-lived, such as an unexpected life event) or chronic (persistent, such as caring for a sick relative or ongoing workplace strain).[15] Chronic stress is thought to have a more detrimental impact on cardiovascular health, largely through sustained autonomic and endocrine dysregulation.[16]

2.1.1 Acute Stress

Acute stress triggers the "fight-or-flight" response via the sympathetic nervous system and the hypothalamic-pituitary-adrenal (HPA) axis, leading to catecholamine release (epinephrine and norepinephrine) and cortisol secretion.[17] These hormones increase heart rate, blood pressure, and myocardial oxygen demand, which can be adaptive in the short term but may provoke adverse cardiac events in susceptible individuals (e.g., those with underlying coronary artery disease).[18]

2.1.2 Chronic Stress

Chronic stress, on the other hand, involves prolonged activation of the HPA axis and sympathetic nervous system, contributing to hypertension, endothelial dysfunction, and the development of a pro-inflammatory and pro-thrombotic state.[19] Over time, chronic stress fosters an environment conducive to atherosclerosis, arrhythmias, and cardiac remodeling.[20]

2.2 Pathophysiological Pathways

2.2.1 Neuroendocrine and Autonomic Pathways

The neuroendocrine system is central to the stress response. Activation of the HPA axis increases cortisol levels, and chronic cortisol elevation is linked to impaired glucose regulation, visceral adiposity, and insulin resistance.[21] Stress-induced sympathetic hyperactivity elevates resting heart rate and blood pressure and contributes to vascular endothelial damage and cardiac hypertrophy.[22]

2.2.2 Immune and Inflammatory Pathways

Stress can dysregulate immune function by enhancing pro-inflammatory cytokine release, such as interleukin-6 and tumor necrosis factor-alpha.[23] Chronic low-grade inflammation has been implicated in the initiation and progression of atherosclerotic plaques, further amplifying cardiovascular risk.[24]

2.2.3 Lifestyle Factors and Health Behaviors

Individuals experiencing high levels of chronic stress are more likely to engage in unhealthy behaviors, such as smoking, excessive alcohol use, physical inactivity, and poor dietary habits.[25] These behaviors synergistically drive the development of CVD and worsen existing heart conditions.[26]

Table 1. Main Pathophysiological Mechanisms of Psychological Factors Affecting the Cardiovascular System

Mechanism	Stress	Depression	Anxiety
Autonomic Nervous System Activation	Increased sympathetic nervous system activity and reduced parasympathetic control	Low heart rate variability (HRV)	Irregular sympathetic activity, tachycardia
HPA Axis and Cortisol Secretion	Chronic cortisol elevation → Metabolic syndrome, visceral obesity	Prolonged cortisol exposure → Insulin resistance, dyslipidemia	Chronic stress response → Disrupted HPA axis and elevated cortisol levels
Inflammatory Processes & Endothelial Dysfunction	Increased proinflammatory cytokines (IL-6, TNF-α)	Elevated CRP, IL-6 levels → Accelerated atherosclerosis	Endothelial damage, elevated CRP

Coagulation & Platelet Activation	–	Increased platelet aggregation → Higher risk of thrombosis	Surges in catecholamines during panic attacks and chronic anxiety
Changes in Health Behaviors	Smoking, alcohol use, eating disorders, physical inactivity	Low treatment adherence, limited exercise, poor dietary habits	Heavy smoking, avoidance behaviors (exercise, social interaction)

Explanation: This table provides a comparative overview of the main pathophysiological mechanisms by which stress, depression, and anxiety impact the cardiovascular system. In clinical practice, it is important to pay attention to the concurrent presence of these mechanisms.

2.3 Epidemiological Evidence

Large-scale epidemiological studies, such as the INTERHEART study, have identified psychosocial stress as an independent risk factor for myocardial infarction.[27] Similarly, data from the Whitehall II study showed that work-related stress was associated with elevated risks of coronary heart disease and poor cardiometabolic profiles.[28] Meta-analyses also corroborate the association between chronic stress and increased CVD risk, underscoring the need for stress management interventions in both primary and secondary prevention strategies.[29]

2.4 Clinical Implications and Management

Stress management approaches include cognitive-behavioral therapy (CBT), mindfulness-based interventions, and relaxation techniques.[30] These interventions can reduce perceived stress, improve autonomic balance, and may modestly reduce blood pressure and heart rate.[31] Encouraging stress-reducing lifestyle modifications—such as regular exercise, sufficient sleep, and social support—can also significantly mitigate cardiovascular risk.[32]

3. Depression and Cardiovascular Health

3.1 The Prevalence of Depression in Cardiac Patients

Depression is notably prevalent among patients with cardiovascular disease, with estimates suggesting that 20% to 40% of post-myocardial infarction patients experience clinically significant depression.[33] This prevalence is substantially higher than that of the general population, indicating a strong relationship between depression and cardiac pathology.[34]

3.2 Pathophysiological Mechanisms

3.2.1 Autonomic Dysfunction

Depression is frequently associated with reduced heart rate variability (HRV), indicating impaired parasympathetic control and/or excessive sympathetic activity.[35] Low HRV is predictive of arrhythmias, adverse coronary events, and increased mortality.[36]

3.2.2 HPA Axis Hyperactivity

Chronic hyperactivity of the HPA axis can result in elevated cortisol levels in depressed individuals. Excess cortisol contributes to central obesity, insulin resistance, and dyslipidemia—all of which are linked to coronary artery disease.[37]

3.2.3 Platelet Activation and Inflammation

Depression has been linked to increased platelet reactivity, which may predispose to thrombus formation.[38] Additionally, pro-inflammatory cytokine levels, such as C-reactive protein (CRP) and interleukin-6, can be elevated in depressed patients, reinforcing the atherosclerotic process.[39]

3.2.4 Behavioral and Lifestyle Factors

Depressive symptoms often coincide with diminished motivation and energy, leading to poor adherence to medical regimens, reduced physical activity, and unhealthy diet choices.[40] Substance use behaviors, including smoking and excessive alcohol intake, can also be exacerbated by depressive symptomatology.[41]

3.3 Clinical and Epidemiological Evidence

Numerous prospective cohort studies and meta-analyses indicate that depression independently increases the risk of incident CVD by approximately 1.5- to 2.0-fold.[42] Post-myocardial infarction patients with major depression demonstrate a two- to three-fold higher risk of mortality within 6 months to a year compared to non-depressed counterparts.[43] Depression in the context of heart failure is likewise associated with increased hospitalizations and worse functional outcomes.[44]

3.4 Assessment and Management in Clinical Practice

Routine screening for depression in cardiac patients is increasingly advocated by professional societies.[45] The Patient Health Questionnaire

(PHQ-9) and the Hospital Anxiety and Depression Scale (HADS) are commonly used screening tools.[46] Evidence-based depression treatments—pharmacological (e.g., selective serotonin reuptake inhibitors) or psychotherapeutic (e.g., CBT, interpersonal therapy)—can significantly improve depressive symptoms and may modestly enhance cardiovascular outcomes.[47,48] Collaborative care models, which integrate mental health services into cardiac rehabilitation, are effective in managing depression in cardiac populations.[49]

4. Anxiety and Cardiovascular Health

4.1 Overview of Anxiety Disorders

Anxiety disorders encompass generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, and phobias.[50] While anxiety is a normal response to stress, pathological anxiety involves persistent worry or fear that impairs daily functioning.[51]

4.2 Mechanisms Linking Anxiety to Cardiovascular Disease

4.2.1 Sympathetic Overdrive and Autonomic Imbalance

Patients with chronic anxiety often exhibit sympathetic hyperresponsiveness, which can lead to elevated blood pressure, tachycardia, and heightened cardiac workload.[52] Over time, these physiological perturbations may contribute to left ventricular hypertrophy and vascular remodeling.[53]

4.2.2 Endothelial Dysfunction and Inflammation

Some evidence suggests that chronic anxiety is associated with endothelial dysfunction—an early marker of atherosclerosis—and elevated inflammatory markers, such as interleukin-6 and CRP.[54]

4.2.3 Behavioral Pathways

Persistent anxiety can promote harmful health behaviors, including smoking, overeating, and avoidance of physical activity, thereby elevating cardiovascular risk.[55] Furthermore, anxiety can undermine adherence to cardiac rehabilitation and medication regimens.[56]

4.3 Epidemiological Findings

Population-based studies indicate a modest but significant association between anxiety disorders and cardiovascular events.[57] In the Nurses' Health Study, phobic anxiety was linked to an increased risk of fatal coronary heart

disease.[58] Likewise, panic disorder has been correlated with elevated risks of cardiovascular morbidity, possibly due to repeated surges in catecholamines during panic attacks.[59]

4.4 Clinical Management

Anxiety screening in cardiac settings can be done using tools such as the Generalized Anxiety Disorder-7 (GAD-7) scale.[60] Treatment modalities include psychotherapy (particularly CBT) and pharmacotherapy (e.g., selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors), which can alleviate anxiety symptoms and potentially improve cardiac outcomes.[61] Stress management techniques and cardiac rehabilitation programs that incorporate relaxation training may further reduce anxiety-related cardiac risks.[62]

Table 2. The Effects of Psychological Risk Factors on Cardiovascular Diseases

Risk Factor	Definition	Prevalence	Increase in Cardiovascular (CV) Risk	Key References
Stress	The physical and emotional response of an individual to external or internal stimuli (stressors).	High job stress, family issues, etc.	Increase in blood pressure, dysregulation of the autonomic nervous system, acceleration of inflammatory processes	Rosengren et al.[19], Kivimäki et al.[26]
Depression	A mood disorder characterized by persistent sadness, loss of interest, low energy, and negative thoughts.	20–40% in those with CV disease	Increased mortality risk, reduced heart rate variability, endothelial dysfunction, increased platelet aggregation	Lichtman et al.[8], Carney & Freedland[10]
Anxiety Disorders	A condition marked by persistent worry, fear, or panic attacks that interfere with daily functioning.	5–15% in the general population (variable)	Heightened sympathetic activity, increased cardiac output, elevated risk of arrhythmias and hypertension	Roest et al.[57], Kawachi et al.[58]
Hostility/ Low Social Support	Negative affect, social isolation, or inadequate support systems.	Variable	Increased inflammation, lower treatment adherence, greater likelihood of risky health behaviors (smoking, alcohol, etc.)	Albus[9], Everson-Rose & Lewis[25]

Explanation: This table briefly summarizes psychological factors, their associated prevalence rates, their contribution to cardiovascular risk, and references.

5. Integrated Psychocardiology Approaches

5.1 Multi-Disciplinary Collaboration

Successful integration of psychological care into cardiology services requires collaboration among cardiologists, psychiatrists, psychologists, and nurses.[63] Such a team-based model ensures that psychosocial issues are identified early and managed appropriately.[64]

5.2 Prevention Strategies and Risk Assessment

Screening for stress, depression, and anxiety should be incorporated into routine cardiovascular risk assessment.[65] Tools like the PHQ-9, HADS, and GAD-7 are quick, validated instruments that can be easily integrated into clinical practice.[66] For individuals at high risk, preventive interventions—such as CBT, stress management, and lifestyle modifications—can be employed to mitigate future cardiovascular events.[67]

5.3 Psychotherapeutic and Behavioral Interventions

A range of psychotherapeutic interventions, including CBT, problem-solving therapy, and motivational interviewing, has been shown to reduce psychological distress and improve cardiac-related health behaviors.[68] Mindfulness-based interventions can also decrease sympathetic overdrive and inflammatory markers.[69]

5.4 Pharmacological Therapies

For patients with moderate to severe depression or anxiety, selective serotonin reuptake inhibitors (SSRIs) remain first-line therapy due to their favorable safety profile, even in the setting of CVD.[70] Tricyclic antidepressants are less favored because of their potential to cause arrhythmias and orthostatic hypotension.[71] When prescribing psychotropic medications, clinicians must be aware of potential drug interactions and effects on blood pressure, heart rate, and QT interval.[72]

5.5 Cardiac Rehabilitation with Psychological Components

Cardiac rehabilitation programs that include psychosocial counseling and stress-management training are associated with better adherence, improved mood, and reduced morbidity and mortality in cardiac patients.[73]

Comprehensive cardiac rehabilitation addresses exercise, nutrition, smoking cessation, and psychological well-being, demonstrating synergistic benefits in reducing cardiovascular risk.[74]

Table 3. Commonly Used Scales and Tests for Psychosocial Assessment in Cardiac Patients

Scale/Test Name	Purpose	Scope / Key Features	Reference
Hospital Anxiety and Depression Scale (HADS)	Screening for anxiety and depression in hospital settings	14 items, 2 subscales (anxiety and depression), fast and practical	Zigmond & Snaith[46]
Patient Health Questionnaire (PHQ-9)	Determining the severity of depression	9-item screening tool, used in both primary care and specialty clinics	Kroenke et al.[60]
Generalized Anxiety Disorder (GAD-7)	Assessment of generalized anxiety disorder	7-item short test, suitable for screening and measuring severity	Spitzer et al.[60]
Beck Depression Inventory (BDI)	Measuring symptoms of major depression	21 items, widely used, requires more time but provides comprehensive assessment	Beck et al.[63]
Beck Anxiety Inventory (BAI)	Measuring anxiety symptoms	21 items, evaluates the severity of both physical and emotional symptoms of anxiety	Beck et al.[63]

Explanation: This table summarizes commonly used psychological assessment tools in cardiac patients. Each scale has different advantages and disadvantages; selection should be based on the clinical setting and patient profile.

Table 4. Psychosocial Interventions in Cardiac Rehabilitation

Type of Intervention	Example Practices	Expected Benefits	References
Cognitive Behavioral Therapy (CBT)	Identifying and reframing negative thought patterns	Improving psychological well-being, enhancing treatment adherence	Freedland et al.[68]
Stress Management Techniques	Meditation, breathing exercises, relaxation training	Reducing sympathetic activity, regulating autonomic balance	Blumenthal et al.[30]

Pharmacotherapy	SSRIs, SNRIs, anxiolytics (if necessary)	Alleviating symptoms of depression and anxiety, limiting negative fluctuations in heart rate and blood pressure	Glassman et al.[47]
Group Therapies / Support Groups	Social support, sharing environment	Decreasing social isolation, strengthening personal coping strategies	Burg et al.[41]
Patient Education and Follow-up	Treatment regimen, lifestyle changes, regular checkups	Increasing treatment adherence, improving long-term survival and quality of life	Katon et al.[49]

Explanation: Including psychosocial interventions in cardiac rehabilitation programs contributes to patient recovery not only in biomedical terms but also in emotional and behavioral dimensions.

6. Future Directions and Research Gaps

Despite the substantial evidence linking stress, depression, and anxiety to cardiovascular disease, several gaps warrant further investigation. First, there is a need to personalize psychocardiology interventions, identifying which patients derive the greatest benefit from specific treatments.[75] Second, the molecular and genetic mechanisms underlying stress-related immune and endocrine dysregulations remain incompletely understood.[76] Third, the development of digital health tools (e.g., mobile apps for stress monitoring, telepsychiatry services) offers promising avenues to expand access to psychocardiology care, but robust data are needed to confirm their efficacy and cost-effectiveness.[77]

Large-scale randomized controlled trials that integrate psychotherapeutic and pharmacological interventions into standard cardiac care can help delineate best practices for comprehensive prevention and management of CVD.[78] Additionally, implementing standardized protocols for routine screening of depression, anxiety, and stress in diverse cardiac populations (e.g., post-MI, heart failure, arrhythmias) will enhance early detection and timely intervention.[79]

7. Conclusion

Psychological factors such as stress, depression, and anxiety exert significant influences on the cardiovascular system through neuroendocrine, autonomic, inflammatory, and behavioral pathways. These factors not only

contribute to the initiation and progression of cardiovascular diseases but also worsen prognosis in patients with established CVD. Psychocardiology thus emerges as an essential discipline, bridging gaps between mental health and cardiology to offer a more holistic approach to patient care.

Effective management strategies should encompass screening for psychological distress, implementing targeted psychotherapy and pharmacotherapy, and integrating these modalities into conventional cardiac rehabilitation programs. By acknowledging the bidirectional interactions between mind and heart, clinicians can improve patient outcomes, reduce hospital readmissions, and ultimately decrease cardiovascular morbidity and mortality. Future research should focus on personalized interventions, innovative digital solutions, and robust clinical trials to continue refining this integral aspect of cardiovascular medicine.

References

Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzansky L. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: The emerging field of behavioral cardiology. J Am Coll Cardiol. 2005;45(5):637-651.

Chida Y, Steptoe A. The association of anger and hostility with future coronary heart disease: a meta-analytic review of prospective evidence. J Am Coll Cardiol. 2009;53(11):936-946.

World Health Organization. Cardiovascular diseases (CVDs). Updated June 2021. Accessed January 15, 2025. https://www.who.int

Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952.

Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29-e39.

DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101-2107.

Franz Alexander F. Psychosomatic Medicine: Its Principles and Applications. W.W. Norton; 1950.

Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations. Circulation. 2014;129(12):1350-1369.

Albus C. Psychological and social factors in coronary heart disease. Ann Med. 2010;42(7):487-494.

Carney RM, Freedland KE. Depression in patients with coronary artery disease. Am J Med. 2008;121(11 Suppl 2):S20-S27.

Van Melle JP, De Jonge P, Spijkerman TA, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med. 2004;66(6):814-822.

Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med. 2004;66(6):802-813.

Whooley MA, de Jonge P, Vittinghoff E, et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA. 2008;300(20):2379-2388.

McEwen BS. Stress, adaptation, and disease: allostasis and allostatic load. Ann N Y Acad Sci. 1998;840:33-44.

Schneiderman N, Ironson G, Siegel SD. Stress and health: psychological, behavioral, and biological determinants. Annu Rev Clin Psychol. 2005;1:607-628.

Cohen S, Janicki-Deverts D, Miller GE. Psychological stress and disease. JAMA. 2007;298(14):1685-1687.

Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors, and stress. J Psychosom Res. 2002;53(4):865-871.

Gullette EC, Blumenthal JA, Babyak M, et al. Effects of mental stress on myocardial ischemia during daily life. JAMA. 1997;277(19):1521-1526.

Rosengren A, Orth-Gomér K, Wedel H, Wilhelmsen L. Stressful life events, social support, and mortality in men born in 1933. BMJ. 1993;307(6912):1102-1105.

Black PH, Garbutt LD. Stress, inflammation and cardiovascular disease. J Psychosom Res. 2002;52(1):1-23.

Bjorntorp P, Rosmond R. Obesity and cortisol. Nutrition. 2000;16(10):924-936.

Thayer JF, Lane RD. A model of neurovisceral integration in emotion regulation and dysregulation. J Affect Disord. 2000;61(3):201-216.

Dhabhar FS. Effects of stress on immune function: the good, the bad, and the beautiful. Immunol Res. 2014;58(2-3):193-210.

Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83(2):456S-460S.

Everson-Rose SA, Lewis TT. Psychosocial factors and cardiovascular diseases. Annu Rev Public Health. 2005;26:469-500.

Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol. 2018;15(4):215-229.

Rosengren A, Hawken S, Ôunpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11,119 cases and 13,648 controls from 52 countries (INTERHEART study): case-control study. Lancet. 2004;364(9438):953-962.

Chandola T, Brunner E, Marmot M. Chronic stress at work and the metabolic syndrome: prospective study. BMJ. 2006;332(7540):521-525.

Steptoe A, Kivimäki M. Stress and cardiovascular disease. Nat Rev Cardiol. 2012;9(6):360-370.

Blumenthal JA, Babyak MA, Doraiswamy PM, et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med. 2007;69(7):587-596.

Esch T, Fricchione GL, Stefano GB. The therapeutic use of the relaxation response in stress-related diseases. Med Sci Monit. 2003;9(2):RA23-RA34.

Wulsin LR, Singal BM. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosom Med. 2003;65(2):201-210.

Dickens C, McGowan L, Percival C, Tomenson B, Creed F. Depression is a risk factor for mortality after myocardial infarction: fact or artifact? J Am Coll Cardiol. 2007;49(18):1834-1840.

Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med. 2000;343(26):1942-1950.

Carney RM, Blumenthal JA, Stein PK, et al. Depression, heart rate variability, and acute myocardial infarction. Circulation. 2001;104(17):2024-2028.

Dekker JM, Crow RS, Folsom AR, et al. Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: the ARIC study. Circulation. 2000;102(11):1239-1244.

Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55(7):580-592.

Sclar DA, Robison LM, Bowen KA, et al. Antidepressant drug use and risk of adverse cardiovascular outcomes: a retrospective population-based study. J Clin Psychiatry. 2012;73(2):184-190.

Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46-56.

DiMatteo MR, Robinson JD, Heritage J, Tabbarah M, Fox SA. Correspondence among patients' self-reports, chart records, and audio/videotapes of medical visits. Health Commun. 2003;15(4):393-413.

Burg MM, Abrams D, Suresh DP, et al. Depression and anxiety predict use of cardiac rehabilitation after coronary artery bypass surgery. J Cardiopulm Rehabil. 2004;24(5):460-467.

Nicholson A, Kuper H, Hemingway H. Depression as an etiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146,538 participants in 54 observational studies. Eur Heart J. 2006;27(23):2763-2774.

Frasure-Smith N, Lespérance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA. 1993;270(15):1819-1825.

Sokoreli I, de Vries JJG, Pauws SC, Steyerberg EW. Depression and anxiety as predictors of mortality among heart failure patients: systematic review and meta-analysis. Heart Fail Rev. 2016;21(1):49-63.

Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment. Circulation. 2008;118(17):1768-1775.

Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370.

Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701-709.

Carney RM, Freedland KE, Steinmeyer B, Blumenthal JA, Berkman LF, Watkins LL. History of depression and survival after acute myocardial infarction. Psychosom Med. 2009;71(3):253-259.

Katon W, Russo J, Lin EH, et al. Cost-effectiveness of a multicondition collaborative care intervention: a randomized controlled trial. Arch Gen Psychiatry. 2012;69(5):506-514.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2013.

Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet. 2006;368(9553):2156-2166.

Watkins LL, Blumenthal JA, Davidson JR, et al. Phobic anxiety, depression, and risk of ventricular arrhythmias in patients with coronary heart disease. Psychosom Med. 2006;68(5):651-656.

Grippo AJ, Johnson AK. Biological mechanisms in the relationship between depression and heart disease. Neurosci Biobehav Rev. 2002;26(8):941-962.

Markovitz JH. Matthews KA, Kannel WB, Cobb JL, D'Agostino RB. Psychological predictors of hypertension in the Framingham Study: is there tension in hypertension? JAMA. 1993;270(20):2439-2443.

Ginty AT, Carroll D, Roseboom TJ, Phillips AC, de Rooij SR. Depression and anxiety are associated with a diagnosis of hypertension 5 years later in a cohort of late middle-aged men and women. J Hum Hypertens. 2013;27(3):187-190.

Thompson DR, Ski CF, Downey JA, et al. A systematic review of the impact of pharmacological agents on outcomes in patients with depression and coronary heart disease. J Psychosom Res. 2015;78(3):175-184.

Roest AM, Martens EJ, de Jonge P, Denollet J. Anxiety and risk of incident coronary heart disease: a meta-analysis. J Am Coll Cardiol. 2010;56(1):38-46.

Kawachi I, Colditz GA, Ascherio A, et al. Prospective study of phobic anxiety and risk of coronary heart disease in men. Circulation. 1994;89(5):1992-1997.

Smoller JW, Pollack MH, Wassertheil-Smoller S, et al. Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women's Health Initiative Observational Study. Arch Gen Psychiatry. 2007;64(10):1153-1160.

Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-1097.

Davidson JR. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry. 2001;62(Suppl 11):46-50.

Gellis ZD, Kang-Yi CD, Meta A, et al. Integrated telehealth care for chronic illness and depression in geriatric home care patients: the Integrated Telehealth Education and Activation of Mood (I-TEAM) study. J Am Geriatr Soc. 2019;67(9):1988-1995.

Albus C, Jordan J, Herrmann-Lingen C. Screening for psychosocial risk factors in patients with coronary heart disease - recommendations for clinical practice. Eur J Prev Cardiol. 2019;26(14):1423-1433.

Watkins LL, Koch GG, Sherwood A, et al. Association of anxiety and depression with all-cause mortality in individuals with coronary heart disease. J Am Heart Assoc. 2013;2(2):e000068.

Ford ES, Wheaton AG, Chapman DP, Li C, Perry GS, Croft JB. Elevated cardiovascular risk among adults with sleep apnea and daytime sleepiness: findings from the National Health and Nutrition Examination Survey 2005-2008. Int J Cardiol. 2014;174(3):610-613.

Smolderen KG, Spertus JA, Reid KJ, et al. The association of cognitive and somatic depressive symptoms with depression recognition and outcomes after myocardial infarction. Circulation. 2009;120(14):1269-1276.

Cohen BE, Edmondson D, Kronish IM. State of the art review: depression, stress, anxiety, and cardiovascular disease. Am J Hypertens. 2015;28(11):1295-1302.

Freedland KE, Skala JA, Carney RM, et al. Treatment of depression after coronary artery bypass surgery (Bypassing the Blues): a randomized controlled trial. JAMA. 2009;302(19):2095-2103.

Creswell JD, Lindsay EK. How does mindfulness training affect health? A mindfulness stress buffering account. Curr Dir Psychol Sci. 2014;23(6):401-407.

Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62(7):792-798.

Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158(11):1774-1782.

Khawaja IS, Westermeyer JJ, Gajwani P, Feinstein RE. Depression and coronary artery disease: the association, mechanism, and therapeutic implications. Psychiatry (Edgmont). 2009;6(1):38-51.

Dalal HM, Doherty P, Taylor RS. Cardiac rehabilitation. BMJ. 2015;351:h5000.

Anderson L, Oldridge N, Thompson DR, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2016;1(1):CD001800.

Albus C, Jordan J, Herrmann-Lingen C. Screening for psychosocial risk factors in patients with coronary heart disease: recommendations for clinical practice. Eur J Cardiovasc Prev Rehabil. 2004;11(2):75-79.

Cohen S, Gianaros PJ, Manuck SB. A stage model of stress and disease. Perspect Psychol Sci. 2016;11(4):456-463.

Sturmberg JP, Martin CM. Handbook of Systems and Complexity in Health. Springer; 2013.

Freedland KE. Depression and coronary heart disease: associations, mechanisms, and treatment. Psychosom Med. 2017;79(8):834-843.

Thombs BD, de Jonge P, Coyne JC, et al. Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA. 2008;300(18):2161-2171.